{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:37:52Z","timestamp":1780475872241,"version":"3.54.1"},"reference-count":234,"publisher":"Elsevier","isbn-type":[{"value":"9780443343735","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.acc.2024.11.001","type":"book-chapter","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T12:21:43Z","timestamp":1736252503000},"page":"1-56","source":"Crossref","is-referenced-by-count":6,"title":["Emerging biomarkers in Gaucher disease"],"prefix":"10.1016","author":[{"given":"Danielle M.","family":"Luettel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia R.","family":"Terluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyeok","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena V.","family":"Kartha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2024.11.001_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1022553819241","article-title":"Clinical and molecular characteristics of Japanese Gaucher disease","volume":"24","author":"Eto","year":"1999","journal-title":"Neurochem. Res."},{"key":"10.1016\/bs.acc.2024.11.001_bib3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2024.11.001_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcmd.2016.10.026","article-title":"Clinical and molecular characteristics of patients with Gaucher disease in Southern China","volume":"68","author":"Feng","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/bs.acc.2024.11.001_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/biomedicines11041067","article-title":"Exploring pro-inflammatory immunological mediators: unraveling the mechanisms of neuroinflammation in lysosomal storage diseases","volume":"11","author":"Pandey","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/17474086.2021.1908120","article-title":"Hematological manifestations and complications of Gaucher disease","volume":"14","author":"Revel-Vilk","year":"2021","journal-title":"Expert. Rev. Hematol."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/gim.2016.159","article-title":"Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening","volume":"19","author":"Yang","year":"2017","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"Ramaswami","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00109-021-02174-z","article-title":"Gaucher disease \u2013 more than just a rare lipid storage disease","volume":"100","author":"Roh","year":"2022","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jclinpath-2020-206580","article-title":"Proteomic biomarkers in Gaucher disease","volume":"74","author":"Pawli\u0144ski","year":"2021","journal-title":"J. Clin. Pathol."},{"issue":"163","key":"10.1016\/bs.acc.2024.11.001_bib15","first-page":"303","article-title":"Biomarkers in clinical medicine","author":"Chen","year":"2011","journal-title":"IARC Sci. Publ."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","article-title":"Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1","volume":"17","author":"Dardis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.acc.2024.11.001_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0027-5107(01)00194-4","article-title":"Validation of biomarkers as early predictors of disease","volume":"481","author":"Bonassi","year":"2001","journal-title":"Mutat. Res."},{"issue":"19","key":"10.1016\/bs.acc.2024.11.001_bib19","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-07-4535","article-title":"Validation of analytic methods for biomarkers used in drug development","volume":"14","author":"Chau","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/bio.15.251","article-title":"AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers","volume":"8","author":"Lowes","year":"2016","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/jpm11070604","article-title":"Standardized outcomes measures in physical therapy practice for treatment and rehabilitation of cerebral PALSY: a systematic review","volume":"11","author":"Apolo-Arenas","year":"2021","journal-title":"J. Pers. Med."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.24945","article-title":"Hyposmia and cognitive impairment in Gaucher disease patients and carriers","volume":"27","author":"McNeill","year":"2012","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/bs.acc.2024.11.001_bib23","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2024.11.001_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79830","article-title":"Neuroinflammation in neuronopathic Gaucher disease: role of microglia and NK cells, biomarkers, and response to substrate reduction therapy","volume":"11","author":"Boddupalli","year":"2022","journal-title":"Elife"},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/10245332.2016.1144336","article-title":"Evaluation of neopterin as a biomarker for the monitoring of Gaucher disease patients","volume":"21","author":"Drugan","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/bs.acc.2024.11.001_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cca.2021.10.029","article-title":"Angiotensin converting enzyme (ACE)","volume":"524","author":"Khurana","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bcmd.2014.07.007","article-title":"Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease","volume":"53","author":"Medrano-Engay","year":"2014","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2019.236083","article-title":"Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data","volume":"106","author":"Raskovalova","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MBC.0b013e3283424809","article-title":"D-dimer assay in Egyptian patients with Gaucher disease: correlation with bone and lung involvement","volume":"22","author":"Sherif","year":"2011","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.10361","article-title":"D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement","volume":"73","author":"Shitrit","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.acc.2024.11.001_bib32","article-title":"The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease","volume":"27","author":"Stiles","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/bs.acc.2024.11.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106794","article-title":"Arterial partial pressure of oxygen and diffusion function as prognostic biomarkers for acute pulmonary embolism","volume":"195","author":"Ye","year":"2022","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skelet. Radiol."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-021-02163-y","article-title":"Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials","volume":"17","author":"Elstein","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/bs.acc.2024.11.001_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/ijd.15341","article-title":"Measuring fatigue: a meta-review","volume":"60","author":"Machado","year":"2021","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/000841749005700207","article-title":"The Canadian occupational performance measure: an outcome measure for occupational therapy","volume":"57","author":"Law","year":"1990","journal-title":"Can. J. Occup. Ther."},{"key":"10.1016\/bs.acc.2024.11.001_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/NDT.S188277","article-title":"Reliability and validity of the depression and somatic symptoms scale among patients with chronic low back pain","volume":"15","author":"Liu","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2019.05.011","article-title":"Gaucher disease type 3c: new patients with unique presentations and review of the literature","volume":"127","author":"Kurolap","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2024.11.001_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123184","article-title":"Measurement of glycosylated ferritin with Concanavalin A: assay design, optimization and validation","volume":"1194","author":"Raynor","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"10","key":"10.1016\/bs.acc.2024.11.001_bib43","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/jbmr.2003.18.10.1905","article-title":"Tartrate-resistant acid phosphatase knockout mice","volume":"18","author":"Hayman","year":"2003","journal-title":"J. Bone Min. Res."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cbf.1133","article-title":"Tartrate-resistant acid phosphatase: a potential target for therapeutic gold","volume":"22","author":"Hayman","year":"2004","journal-title":"Cell Biochem. Funct."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib45","first-page":"S25","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"14","key":"10.1016\/bs.acc.2024.11.001_bib47","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.3390\/ijms21145168","article-title":"Covid-19: The rollercoaster of fibrin(ogen), D-dimer, Von Willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes","volume":"21","author":"Grobler","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/bs.acc.2024.11.001_bib48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"20","key":"10.1016\/bs.acc.2024.11.001_bib49","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1073\/pnas.81.20.6506","article-title":"Cross-reacting material in Gaucher disease fibroblasts","volume":"81","author":"Beutler","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"21","key":"10.1016\/bs.acc.2024.11.001_bib51","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Med. (Baltim.)"},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101522","article-title":"The international cooperative Gaucher group (ICCG) Gaucher registry","volume":"36","author":"Weinreb","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj3030377","article-title":"Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease","volume":"303","author":"Meivar-Levy","year":"1994","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcw002","article-title":"Residual enzymatic activity as a prognostic factor in patients with Gaucher disease type 1: correlation with Zimran and GAUSS-I index and the severity of bone disease","volume":"109","author":"Torralba","year":"2016","journal-title":"QJM"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2017.10.011","article-title":"Tandem mass spectrometry assay of \u03b2-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay","volume":"123","author":"Wolf","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib57","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3572","article-title":"Flow cytometry measurement of glucocerebrosidase activity in human monocytes","volume":"10","author":"Hughes","year":"2020","journal-title":"Bio Protoc."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib58","doi-asserted-by":"crossref","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","article-title":"Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease","volume":"8","author":"Atashrazm","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib59","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3233\/JPD-202508","article-title":"Glucocerebrosidase activity is reduced in cryopreserved Parkinson\u2019s disease patient monocytes and inversely correlates with motor severity","volume":"11","author":"Hughes","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet. Test."},{"issue":"16","key":"10.1016\/bs.acc.2024.11.001_bib61","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \"asymptomatic\" homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib62","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8659","key":"10.1016\/bs.acc.2024.11.001_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","article-title":"Prediction of severity of Gaucher\u2019s disease by identification of mutations at DNA level","volume":"2","author":"Zimran","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-020-01656-6","article-title":"The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients","volume":"16","author":"Deegan","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"10.1016\/bs.acc.2024.11.001_bib65","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.12379","article-title":"A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease","volume":"93","author":"Di Rocco","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00431-012-1830-5","article-title":"A disease severity scoring system for children with type 1 Gaucher disease","volume":"172","author":"Kallish","year":"2013","journal-title":"Eur. J. Pediatr."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Med. (Baltim.)"},{"key":"10.1016\/bs.acc.2024.11.001_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ymgme.2020.03.006","article-title":"Acoustic radiation force impulse point shear wave elastography of the liver and spleen in patients with Gaucher disease type 1: correlations with clinical data and markers of disease severity","volume":"130","author":"Lollert","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymgme.2017.10.013","article-title":"Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients","volume":"123","author":"Serai","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/bs.acc.2024.11.001_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168135","article-title":"Time of initiating enzyme replacement therapy affects immune abnormalities and disease severity in patients with Gaucher disease","volume":"11","author":"Limgala","year":"2016","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/bs.acc.2024.11.001_bib73","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/diagnostics13172812","article-title":"Insights into the value of Lyso-Gb1 as a predictive biomarker in treatment-Na\u00efve patients with Gaucher disease type 1 in the LYSO-PROOF study","volume":"13","author":"Curado","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/bs.acc.2024.11.001_bib74","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87537","article-title":"Osteonecrosis in Gaucher disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center","volume":"12","author":"Basiri","year":"2023","journal-title":"Elife"},{"issue":"14","key":"10.1016\/bs.acc.2024.11.001_bib75","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.3390\/ijms22147699","article-title":"Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations","volume":"22","author":"Dinur","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2024.11.001_bib76","first-page":"117","article-title":"Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients","volume":"7","author":"Deroma","year":"2013","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2010.09.005","article-title":"Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage","volume":"46","author":"Giraldo","year":"2011","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","article-title":"Enzyme replacement therapy \"drug holiday\": results from an unexpected shortage of an orphan drug supply in Australia","volume":"46","author":"Goldblatt","year":"2011","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00005-014-0308-8","article-title":"Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3","volume":"63","author":"Machaczka","year":"2015","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib82","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/bjh.17693","article-title":"Experts\u2019 views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease","volume":"195","author":"Hamiel","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2020.05.002","article-title":"Gaucher disease and SARS-CoV-2 infection: emerging management challenges","volume":"130","author":"Mistry","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2020.12.288","article-title":"Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York","volume":"132","author":"Fierro","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib85","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"Van Dussen","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-023-01131-9","article-title":"Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer","volume":"56","author":"Yu","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib87","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/imj.15858","article-title":"Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher disease","volume":"53","author":"Gan","year":"2023","journal-title":"Intern. Med. J."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib88","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.acc.2024.11.001_bib89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bcmd.2007.06.013","article-title":"Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity","volume":"39","author":"Lee","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"issue":"16","key":"10.1016\/bs.acc.2024.11.001_bib91","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib92","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/ijms23031627","article-title":"Gaucher disease diagnosis using Lyso-Gb1 on dry blood spot samples: time to change the paradigm?","volume":"23","author":"Dinur","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107527","article-title":"Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1","volume":"138","author":"Peterschmitt","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib94","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1055\/a-1642-4206","article-title":"Platelet activation and reactivity in a large cohort of patients with Gaucher disease","volume":"122","author":"Revel-Vilk","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/bs.acc.2024.11.001_bib95","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib96","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/bs.acc.2024.11.001_bib97","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.26675","article-title":"Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry","volume":"97","author":"Rosenbloom","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"40","key":"10.1016\/bs.acc.2024.11.001_bib98","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/bs.acc.2024.11.001_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277058","article-title":"Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells","volume":"17","author":"Stahl-Meyer","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","article-title":"Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3","volume":"14","author":"Schueler","year":"2003","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib101","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/08880018.2021.1989098","article-title":"Abdominal lymphadenopathy in children with Gaucher disease: relation to disease severity and glucosylsphingosine","volume":"39","author":"Tantawy","year":"2022","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib102","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/imj.14156","article-title":"Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative","volume":"49","author":"Mehta","year":"2019","journal-title":"Intern. Med. J."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100199","article-title":"Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish","volume":"63","author":"Lelieveld","year":"2022","journal-title":"J. Lipid Res."},{"issue":"45","key":"10.1016\/bs.acc.2024.11.001_bib104","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/bs.acc.2024.11.001_bib105","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib106","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2018.06.007","article-title":"Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease","volume":"124","author":"Reed","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.011","article-title":"Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1","volume":"25","author":"Cox","year":"2023","journal-title":"Genet. Med."},{"issue":"11","key":"10.1016\/bs.acc.2024.11.001_bib108","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.acc.2024.11.001_bib109","article-title":"Diagnostic and prognostic biomarkers for myocardial infarction","volume":"7","author":"Wu","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"77","key":"10.1016\/bs.acc.2024.11.001_bib110","first-page":"273","article-title":"Gaucher disease: insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"issue":"12","key":"10.1016\/bs.acc.2024.11.001_bib111","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/dmcn.15334","article-title":"Niemann-Pick type C disease as proof-of-concept for intelligent biomarker panel selection in neurometabolic disorders","volume":"64","author":"Papandreou","year":"2022","journal-title":"Dev. Med. Child. Neurol."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib112","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/biom10040526","article-title":"Effect of substrate reduction therapy in comparison to enzyme replacement therapy on immune aspects and bone involvement in Gaucher disease","volume":"10","author":"Limgala","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib113","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"Van Breemen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib114","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00277-015-2354-7","article-title":"Osteopontin: a potential biomarker of Gaucher disease","volume":"94","author":"Vairo","year":"2015","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib115","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2011-0162","article-title":"Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease","volume":"96","author":"van Dussen","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2710.2001.00358.x","article-title":"Neopterin measurement in clinical diagnosis","volume":"26","author":"Berdowska","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"issue":"8","key":"10.1016\/bs.acc.2024.11.001_bib117","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ajmg.a.62252","article-title":"Elevated holo-transcobalamin in Gaucher disease type II: a case report","volume":"185","author":"Basgalupp","year":"2021","journal-title":"Am. J. Med. Genet. A"},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib118","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1091\/mbc.e04-01-0048","article-title":"Cyclase-associated protein 1 (CAP1) promotes cofilin-induced actin dynamics in mammalian nonmuscle cells","volume":"15","author":"Bertling","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib119","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/002215549904700210","article-title":"Localization and expression of tissue kallikrein and kallistatin in human blood vessels","volume":"47","author":"Wolf","year":"1999","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1039\/D2MO00004K","article-title":"Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders","volume":"18","author":"Li","year":"2022","journal-title":"Mol. Omics"},{"key":"10.1016\/bs.acc.2024.11.001_bib121","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.08.004","article-title":"Association between progranulin and Gaucher disease","volume":"11","author":"Jian","year":"2016","journal-title":"EBioMedicine"},{"issue":"1\u20132","key":"10.1016\/bs.acc.2024.11.001_bib122","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgme.2019.07.014","article-title":"Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease","volume":"128","author":"Afinogenova","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2024.11.001_bib123","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/117727190700200023","article-title":"Human chitinases and chitinase-like proteins as indicators for inflammation and cancer","volume":"2","author":"Kzhyshkowska","year":"2007","journal-title":"Biomark Insights"},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib124","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","article-title":"Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K","volume":"96","author":"Moran","year":"2000","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2024.11.001_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101106","article-title":"Cathepsin S (CTSS) activity in health and disease \u2013 a treasure trove of untapped clinical potential","volume":"88","author":"Smyth","year":"2022","journal-title":"Mol. Asp. Med."},{"issue":"7643","key":"10.1016\/bs.acc.2024.11.001_bib126","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"Pandey","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.acc.2024.11.001_bib127","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/jcm10102217","article-title":"TRAP5b and RANKL\/OPG predict bone pathology in patients with Gaucher disease","volume":"10","author":"Ivanova","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/epr.09.54","article-title":"Gaucher disease: a model disorder for biomarker discovery","volume":"6","author":"Boot","year":"2009","journal-title":"Expert. Rev. Proteom."},{"issue":"9","key":"10.1016\/bs.acc.2024.11.001_bib129","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/2211-5463.12078","article-title":"Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models","volume":"6","author":"Kramer","year":"2016","journal-title":"FEBS Open. Bio"},{"key":"10.1016\/bs.acc.2024.11.001_bib130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2016.12.002","article-title":"Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease","volume":"68","author":"Murugesan","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"issue":"1\u20132","key":"10.1016\/bs.acc.2024.11.001_bib131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gene.2008.01.014","article-title":"Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB","volume":"413","author":"Ripoll","year":"2008","journal-title":"Gene"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib132","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/ijms20010066","article-title":"Glycoprotein non-metastatic protein B: an emerging biomarker for lysosomal dysfunction in macrophages","volume":"20","author":"Van Der Lienden","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120194","article-title":"Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease","volume":"10","author":"Zigdon","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib134","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/s41467-023-37685-5","article-title":"Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders","volume":"14","author":"Eide","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2024.11.001_bib135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fnins.2020.00579","article-title":"Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value","volume":"14","author":"Loeffler","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/bs.acc.2024.11.001_bib136","article-title":"Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients","volume":"30","author":"Welford","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib137","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib138","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/biom11040576","article-title":"The role of exosomes in lysosomal storage disorders","volume":"11","author":"Gleason","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/bs.acc.2024.11.001_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2020.104038","article-title":"Altered level of plasma exosomes in patients with Gaucher disease","volume":"63","author":"Tatiana","year":"2020","journal-title":"Eur. J. Med. Genet."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib140","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/diagnostics12061414","article-title":"Quantitation of a urinary profile of biomarkers in Gaucher disease type 1 patients using tandem mass spectrometry","volume":"12","author":"Menkovic","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"18","key":"10.1016\/bs.acc.2024.11.001_bib141","doi-asserted-by":"crossref","first-page":"10387","DOI":"10.3390\/ijms231810387","article-title":"Serum phospholipid profile changes in Gaucher disease and Parkinson\u2019s disease","volume":"23","author":"L\u00f3pez de Frutos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib142","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/biom13040644","article-title":"Alpha-synuclein mRNA level found dependent on L444P variant in carriers and Gaucher disease patients on enzyme replacement therapy","volume":"13","author":"Dubiela","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/bs.acc.2024.11.001_bib143","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neulet.2014.09.041","article-title":"Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases","volume":"583","author":"Pchelina","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.acc.2024.11.001_bib144","article-title":"Patients with Gaucher disease display systemic oxidative stress dependent on therapy status","volume":"25","author":"Kartha","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12011-019-01709-3","article-title":"Oxidative stress parameters, trace elements, and lipid profile in Iranian patients with Gaucher disease","volume":"193","author":"Mozafari","year":"2020","journal-title":"Biol. Trace Elem. Res."},{"issue":"16","key":"10.1016\/bs.acc.2024.11.001_bib146","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.3390\/ijms23169189","article-title":"Biological variation in peripheral inflammation and oxidative stress biomarkers in individuals with Gaucher disease","volume":"23","author":"Sahasrabudhe","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib147","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib148","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10545-009-1064-5","article-title":"Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy","volume":"32","author":"Van Breemen","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib149","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","article-title":"Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease","volume":"28","author":"Drugan","year":"2002","journal-title":"Blood Cell Mol. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib151","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","article-title":"Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy","volume":"28","author":"Schiffmann","year":"2002","journal-title":"Blood Cell Mol. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00223-001-2072-0","article-title":"Bone marker alterations in patients with type 1 Gaucher disease","volume":"72","author":"Ciana","year":"2003","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib153","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","article-title":"Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy","volume":"28","author":"Ciana","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib154","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/bs.acc.2024.11.001_bib155","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/TCRM.S177480","article-title":"Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1","volume":"14","author":"Zimmermann","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib156","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","article-title":"Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat","volume":"83","author":"Mikosch","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib157","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/157016111794519372","article-title":"Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology","volume":"9","author":"De Rosa","year":"2011","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/bs.acc.2024.11.001_bib158","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2016.09.050","article-title":"Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson\u2019s disease","volume":"370","author":"Campolo","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"20","key":"10.1016\/bs.acc.2024.11.001_bib159","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJM197611112952002","article-title":"Increased circulating levels of transcobalamin ii in Gaucher\u2019s disease","volume":"295","author":"Gilbert","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib160","doi-asserted-by":"crossref","first-page":"359S","DOI":"10.3945\/ajcn.111.013458","article-title":"Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility","volume":"94","author":"Nexo","year":"2011","journal-title":"Am. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib161","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrn.2017.36","article-title":"Progranulin, lysosomal regulation and neurodegenerative disease","volume":"18","author":"Kao","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/bs.acc.2024.11.001_bib162","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ebiom.2018.01.022","article-title":"Chitinase-3-like protein 1: a progranulin downstream molecule and potential biomarker for Gaucher disease","volume":"28","author":"Jian","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2024.11.001_bib163","first-page":"281","article-title":"[Cathepsin K as a biomarker of bone involvement in type 1 Gaucher disease]","volume":"145","author":"Bobillo Lobato","year":"2015"},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib164","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms22052532","article-title":"GCase and LIMP2 abnormalities in the liver of niemann pick type C mce","volume":"22","author":"van der Lienden","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","article-title":"Cathepsin D\u2014many functions of one aspartic protease","volume":"68","author":"Benes","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"18","key":"10.1016\/bs.acc.2024.11.001_bib166","doi-asserted-by":"crossref","first-page":"9912","DOI":"10.3390\/ijms22189912","article-title":"C5a activates a pro-inflammatory gene expression profile in human Gaucher iPSC-derived macrophages","volume":"22","author":"Serfecz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib167","first-page":"165","article-title":"Gaucher disease: the role of the specialist on metabolic bone diseases","volume":"12","author":"Masi","year":"2015","journal-title":"Clin. Cases Min. Bone Metab."},{"issue":"23-24","key":"10.1016\/bs.acc.2024.11.001_bib168","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","article-title":"An overview on bone manifestations in Gaucher disease","volume":"160","author":"Mikosch","year":"2010","journal-title":"Wien. Med. Wochenschr."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib169","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.2000.15.7.1337","article-title":"Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption","volume":"15","author":"Halleen","year":"2000","journal-title":"J. Bone Min. Res."},{"issue":"9\u201310","key":"10.1016\/bs.acc.2024.11.001_bib170","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin. Lab."},{"key":"10.1016\/bs.acc.2024.11.001_bib171","series-title":"Biomarkers in Disease: Methods, Discoveries and Applications","article-title":"General methods in biomarker research and their applications","author":"Preedy","year":"2015"},{"issue":"8","key":"10.1016\/bs.acc.2024.11.001_bib172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012093","article-title":"ADAM10 releases a soluble form of the GPNMB\/Osteoactivin extracellular domain with angiogenic properties","volume":"5","author":"Rose","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.11.001_bib173","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.steroids.2017.10.013","article-title":"Glycoprotein non-metastatic melanoma protein B (GPNMB) and cancer: a novel potential therapeutic target","volume":"133","author":"Taya","year":"2018","journal-title":"Steroids"},{"issue":"13","key":"10.1016\/bs.acc.2024.11.001_bib174","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.yexcr.2008.02.006","article-title":"Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function","volume":"314","author":"Abdelmagid","year":"2008","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jcb.1259","article-title":"Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts","volume":"84","author":"Safadi","year":"2001","journal-title":"J. Cell Biochem."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib176","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib177","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib178","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ymgme.2021.11.315","article-title":"Neurofilament light chain: a potential marker of neurological disease in Gaucher disease","volume":"135","author":"Terluk","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib179","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson\u2019s disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"15","key":"10.1016\/bs.acc.2024.11.001_bib180","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.3390\/ijms21155188","article-title":"Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients","volume":"21","author":"Bhalla","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib181","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/0004867419893431","article-title":"Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response","volume":"54","author":"Eratne","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib182","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib183","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.3390\/ijms21072576","article-title":"Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic- and endo-lysosomal systems go extracellular","volume":"21","author":"Buratta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib184","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2019.10.006","article-title":"GBA1 mutations: prospects for exosomal biomarkers in \u03b1-synuclein pathologies","volume":"129","author":"Johnson","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2024.11.001_bib185","first-page":"53","article-title":"A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease","volume":"3","author":"Machaczka","year":"2012","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib186","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"1\u20132","key":"10.1016\/bs.acc.2024.11.001_bib187","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","article-title":"Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention","volume":"1781","author":"Groener","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"1-2","key":"10.1016\/bs.acc.2024.11.001_bib188","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib189","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cell Mol. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib190","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2017.12.431","article-title":"Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature","volume":"123","author":"Voorink-Moret","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"20","key":"10.1016\/bs.acc.2024.11.001_bib191","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1182\/bloodadvances.2023009890","article-title":"Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma","volume":"7","author":"Gudgeon","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib192","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib193","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ymgme.2007.11.011","article-title":"Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease","volume":"93","author":"Fuller","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib194","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejim.2013.09.006","article-title":"Gaucher disease: a diagnostic challenge for internists","volume":"25","author":"Cassinerio","year":"2014","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib195","first-page":"106","article-title":"Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses","volume":"24","author":"Cox","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib196","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/biomedicines11041051","article-title":"Urinary biomarkers and point-of-care urinalysis devices for early diagnosis and management of disease: a review","volume":"11","author":"Sequeira-Antunes","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib197","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0009-8981(86)90231-7","article-title":"Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease","volume":"158","author":"Aerts","year":"1986","journal-title":"Clin. Chim. Acta"},{"issue":"447","key":"10.1016\/bs.acc.2024.11.001_bib198","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2005.tb02110.x","article-title":"Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases","volume":"94","author":"Aerts","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib199","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10545-006-0318-8","article-title":"CCL18: a urinary marker of Gaucher cell burden in Gaucher patients","volume":"29","author":"Boot","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcmd.2015.01.006","article-title":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","volume":"54","author":"Mirzaian","year":"2015","journal-title":"Blood Cell Mol. Dis."},{"issue":"9","key":"10.1016\/bs.acc.2024.11.001_bib201","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-020-00746-0","article-title":"Enhancing the activity of glucocerebrosidase as a treatment for Parkinson disease","volume":"34","author":"Menozzi","year":"2020","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"issue":"28","key":"10.1016\/bs.acc.2024.11.001_bib203","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/bs.acc.2024.11.001_bib204","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.23774","article-title":"Lysosomal storage disorders and Parkinson\u2019s disease: Gaucher disease and beyond","volume":"26","author":"Shachar","year":"2011","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.26200","article-title":"Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease","volume":"30","author":"Nuzhnyi","year":"2015","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib206","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277602","article-title":"a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy","volume":"18","author":"Moraitou","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib207","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neulet.2012.08.069","article-title":"Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging","volume":"528","author":"Argyriou","year":"2012","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib208","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib209","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1148\/radiol.2273020518","article-title":"Biomarkers in imaging: realizing radiology\u2019s future","volume":"227","author":"Smith","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/bs.acc.2024.11.001_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109091","article-title":"Enhanced vertebra to disk ratio as a new semi-quantitative imaging biomarker for Gaucher disease patients","volume":"129","author":"Beaumont","year":"2020","journal-title":"Eur. J. Radiol."},{"issue":"10","key":"10.1016\/bs.acc.2024.11.001_bib211","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00415-013-7011-2","article-title":"Clinical, genetic, and brain sonographic features related to Parkinson\u2019s disease in Gaucher disease","volume":"260","author":"B\u00f6ttcher","year":"2013","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib212","first-page":"S61","article-title":"Gaucher disease \u2013 bone involvement","volume":"94","author":"Chis","year":"2021","journal-title":"Med. Pharm. Rep."},{"issue":"6","key":"10.1016\/bs.acc.2024.11.001_bib213","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajmg.a.32253","article-title":"The Erlenmeyer flask bone deformity in the skeletal dysplasias","volume":"149A","author":"Faden","year":"2009","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/bs.acc.2024.11.001_bib214","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejrad.2018.02.014","article-title":"Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging","volume":"102","author":"Kang","year":"2018","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ymgme.2019.10.013","article-title":"Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease","volume":"129","author":"Lipi\u0144ski","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.acc.2024.11.001_bib216","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clinimag.2021.06.002","article-title":"Diffusion tensor imaging of vertebral bone marrow in children with Gaucher\u2019s disease type I and III: pre- and post-therapy","volume":"79","author":"Razek","year":"2021","journal-title":"Clin. Imaging"},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib217","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","article-title":"Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease","volume":"26","author":"Vlieger","year":"2002","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"11","key":"10.1016\/bs.acc.2024.11.001_bib218","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00234-019-02286-x","article-title":"Diagnostic accuracy of diffusion tensor imaging in differentiating malignant from benign compressed vertebrae","volume":"61","author":"Razek","year":"2019","journal-title":"Neuroradiology"},{"key":"10.1016\/bs.acc.2024.11.001_bib219","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fneur.2018.00092","article-title":"Understanding the physiopathology behind axial and radial diffusivity changes\u2014what do we know?","volume":"9","author":"Winklewski","year":"2018","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/bs.acc.2024.11.001_bib220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00234-009-0548-1","article-title":"Apparent diffusion coefficient vale of the brain in patients with Gaucher\u2019s disease type II and type III","volume":"51","author":"Abdel Razek","year":"2009","journal-title":"Neuroradiology"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib221","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00256-012-1464-8","article-title":"Apparent diffusion coefficient of the vertebral bone marrow in children with Gaucher\u2019s disease type I and III","volume":"42","author":"Razek","year":"2013","journal-title":"Skelet. Radiol."},{"key":"10.1016\/bs.acc.2024.11.001_bib222","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bcmd.2016.12.004","article-title":"Assessment of the liver and spleen in children with Gaucher disease type I with diffusion-weighted MR imaging","volume":"68","author":"Razek","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib223","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1361-8415(02)00053-1","article-title":"Processing and visualization for diffusion tensor MRI","volume":"6","author":"Westin","year":"2002","journal-title":"Med. Image Anal."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib224","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.chi.0000246064.93200.e8","article-title":"Diffusion tensor imaging: application to the study of the developing brain","volume":"46","author":"Cascio","year":"2007","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib225","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10545-011-9288-6","article-title":"Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging","volume":"34","author":"Davies","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib226","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2012.04.002","article-title":"Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment","volume":"49","author":"Mekinian","year":"2012","journal-title":"Blood Cell Mol. Dis."},{"issue":"7","key":"10.1016\/bs.acc.2024.11.001_bib227","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/bs.acc.2024.11.001_bib228","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.immuni.2023.01.008","article-title":"Direct activation of microglia by \u03b2-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease","volume":"56","author":"Shimizu","year":"2023","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/bs.acc.2024.11.001_bib229","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000433438","article-title":"Imaging in glucocerebrosidase-associated Parkinsonism: current status and implications for pathophysiology","volume":"15","author":"Kiferle","year":"2015","journal-title":"Neurodegener. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2024.11.001_bib230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.parkreldis.2012.12.006","article-title":"Transcranial sonography in patients with Parkinson\u2019s disease with glucocerebrosidase mutations","volume":"19","author":"Kresojevi\u0107","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/bs.acc.2024.11.001_bib231","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2016.10.001","article-title":"Liver involvement in Gaucher disease \u2013 review and clinical approach","volume":"68","author":"Adar","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2024.11.001_bib232","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057507","article-title":"Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage","volume":"8","author":"Bohte","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.acc.2024.11.001_bib233","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13244-019-0743-5","article-title":"Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement","volume":"10","author":"Degnan","year":"2019","journal-title":"Insights Imaging"},{"issue":"12","key":"10.1016\/bs.acc.2024.11.001_bib234","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00234-018-2116-z","article-title":"Thalamic and dentate nucleus abnormalities in the brain of children with Gaucher disease","volume":"60","author":"Perucca","year":"2018","journal-title":"Neuroradiology"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232400132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232400132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T13:27:00Z","timestamp":1736861220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006524232400132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443343735"],"references-count":234,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2024.11.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}